Novartis AG ADR (NVS)vsOlema Pharmaceuticals Inc (OLMA)

NVS

Novartis AG ADR

NYSE

$137.16

-0.23%

HEALTHCARE · Cap: $260.70B

OLMA

Olema Pharmaceuticals Inc

NASDAQ

$10.22

-4.40%

HEALTHCARE · Cap: $961.16M

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

NVS leads profitability with a 22.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).

NVS

Buy

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 4.5

Piotroski: 4/9Altman Z: 1.96

OLMA

Avoid

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 8.0

Piotroski: 1/9Altman Z: 3.70

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-47.0%)

Margin of Safety

-47.0%

Fair Value

$93.29

Current Price

$137.16

$43.87 premium

UndervaluedFair: $93.29Overvalued

Intrinsic value data unavailable for OLMA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS5 strengths · Avg: 9.4/10

Market CapQuality

$260.70B10/10

Mega-cap, among the largest globally

Return on EquityProfitability

30.7%10/10

Every $100 of equity generates 31 in profit

Operating MarginProfitability

34.6%10/10

Strong operational efficiency at 34.6%

Profit MarginProfitability

22.5%9/10

Keeps 23 of every $100 in revenue as profit

Free Cash FlowQuality

$5.57B8/10

Generating 5.6B in free cash flow

OLMA3 strengths · Avg: 9.3/10

Debt/EquityHealth

0.0010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth

3.7010/10

Safe zone — low bankruptcy risk

Price/BookValuation

2.1x8/10

Reasonable price relative to book value

Areas to Watch

NVS4 concerns · Avg: 3.3/10

Revenue GrowthGrowth

0.8%4/10

0.8% revenue growth

Altman Z-ScoreHealth

1.964/10

Grey zone — moderate risk

Debt/EquityHealth

1.183/10

Elevated debt levels

PEG RatioValuation

3.222/10

Expensive relative to growth rate

OLMA4 concerns · Avg: 3.5/10

Revenue GrowthGrowth

0.0%4/10

0.0% revenue growth

EPS GrowthGrowth

0.0%4/10

0.0% earnings growth

Market CapQuality

$961.16M3/10

Smaller company, higher risk/reward

Profit MarginProfitability

0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.

Bull Case : OLMA

The strongest argument for OLMA centers on Debt/Equity, Altman Z-Score, Price/Book.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.

Bear Case : OLMA

The primary concerns for OLMA are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

OLMA carries more volatility with a beta of 1.99 — expect wider price swings.

NVS is growing revenue faster at 0.8% — sustainability is the question.

NVS generates stronger free cash flow (5.6B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NVS scores higher overall (51/100 vs 28/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company is headquartered in San Francisco, California.

Compare with Other DRUG MANUFACTURERS - GENERAL Stocks

NVS vs LLY NVS vs JNJ NVS vs ABBV NVS vs MRK NVS vs AZN OLMA vs LLY OLMA vs JNJ OLMA vs ABBV OLMA vs MRK OLMA vs AZN

Want to dig deeper into these stocks?

Full NVS Analysis →Full OLMA Analysis →